UroGen Pharma Ltd. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
UroGen Pharma Ltd. (URGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 496.42 thousand shares for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-24.
Discontinued › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2023-03-24
- UroGen Pharma Ltd. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 496.42K shares, a 46.99% increase from fiscal 2021.
- UroGen Pharma Ltd. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2021 was 337.72K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|
| 2022-12-31 | 496.42K shares 10-K · filed 2023-03-24 |
| 2021-12-31 | 337.72K shares 10-K · filed 2023-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |